 |
Joint
Care eNews #3 / August 2005 |
| Joint Care Headlines | ||||
| CS
Bio-Active: The Chondroitin tested in the NIH Trial A few months away from the publication of the results of the NIH Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), the biggest independent clinical trial ever carried out into osteoarthritis, there is a climate of great expectation in the scientific community and pharmaceutical industry. (more) Bioiberica Symposium at the ACR Meeting For the first time, the preliminary results of the GAIT Trial will be discussed at a Bioiberica symposium during the ACR Meeting. The results of the trial, carried out by the NIH using CS Bio-Active, Bioiberica's chondroitin, are expected to open up new perspectives in chondroprotection. (more) Bioiberica presents its recent scientific findings during the Spanish Rheumatology Society (SER) conference The results of this research represent an important finding in the treatment of osteoarthritis. For the first time, they provide evidence that a Symptomatic OA Drug , Chondroitin Sulfate (CS), acts on osteoarthritic subchondral bone. (more) |
||||
|
| ||||
| Joint Care News | ||||
| CS Bio-Active: The Chondroitin tested in the NIH
Trial A few months away from the publication of the results of the NIH Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), the biggest independent clinical trial ever carried out into osteoarthritis, there is a climate of great expectation in the scientific community and pharmaceutical industry. Conducted by the National Institutes of Health in the United States, the study involves a sample of some 1600 patients and compares the clinical efficacy of Bioibérica´s Chondroitin Sulfate - CS Bio-Active - with glucosamine hydrochloride, used separately or in combination, in the treatment of osteoarthritis. The results of this study are expected to be revealing, given that it will be the first of its kind to compare the clinical efficacy and safety of these molecules separately and in combination. Once again, Bioibérica's chondroitin sulfate, CS Bio-Active, has shown itself to be the product of reference. Chosen by the NIH to be tested in this ambitious study, CS Bio-Active is the only Chondroitin Sulfate on the market with proven clinical efficacy. (top) Bioiberica Symposium at the ACR Meeting For the first time, the preliminary results of the GAIT Trial will be discussed at a Bioiberica symposium during the ACR Meeting. The results of the trial, carried out by the NIH using CS Bio-Active, Bioiberica's chondroitin, are expected to open up new perspectives in chondroprotection. The symposium, entitled "Chondroitin Sulfate: Mechanisms of Action and Clinical Response in Osteoarthritis", will take place on 17 November 2005 during the American College of Rheumatology's Annual Scientific Meeting in San Diego. Internationally-renowned researchers in the field of Rheumatology will discuss the preliminary GAIT results and carry out an extensive review of Chondroitin Sulfate (CS Bio-Active) pre-clinical and clinical data. This symposium is designed to provide the medical community with all the relevant information and new clinical data regarding Chondroitin Sulfate (CS Bio-Active), from its mechanisms of action and pharmacokinetics to the latest clinical-trial results and evidence of its structure/disease modifying effect. (top) Bioiberica presents its recent scientific findings during the Spanish Rheumatology Society (SER) conference The results of this research represent an important finding in the treatment of osteoarthritis. For the first time, they provide evidence that a Symptomatic OA Drug , Chondroitin Sulfate (CS), acts on osteoarthritic subchondral bone. The findings, which were received with great interest by the medical community, were presented by Bioibérica's Scientific Medical Department during the 31st conference of the Spanish Rheumatology Society (SER) in May this year . The research was carried out by Bioiberica in conjunction with the research team led by Professors J Martel-Pelletier and JP Pelletier of the OA Research Unit at the University of Montreal with the objective of identifying the mechanisms of action of CS on subchondral bone. In osteoarthritis, subchondral bone is affected causing it to be considered one of the principle characteristics of the pathology along with cartilage deterioration and inflammation of the synovial membrane. Through the use of an in vitro model, the findings help explain the mechanisms by which CS has beneficial effects on the process of remodelling subchondral bone in osteoarthritis. In other words, these findings provide evidence of CS's chondroprotective action and capacity to modify the course of osteoarthritic disease. (top) |
||||
| Short News | ||
| New
members of staff Two new members of staff have recently joined the Joint Care Division: Kristján Ferrer and Vanesa Villarreal. Kristján will be Area Manager for Europe and its area of influence, working with Sonia Jiménez. Vanesa will be filling the post of Sales Assistant, looking after clients and handling orders. Glucosamine licence granted to Almirall Bioiberica has granted a licence to Almirall Prodesfarma to market Glucosamine as a Rx Drug in Spain under their own brand. Currently domestic most important pharmaceutical company, Almirall has already successfully launched the product on the market. CPHI 2005 Please visit us at CPHI Worldwide 2005, stand 8J29 at the Feria de Madrid (Spain), 1-3 November, 2005. Supplyside West 2005 Please visit us at supplyside west 2005, stand 6067 at the venetian & Sands Expo, Las Vegas (USA), 9-11 November, 2005. |
||
| Latest eNews | ||
| You can read previous numbers of Joint Care
eNews online at our website: Number 1 Number 2 |
||
| Our Products | ||
 | ||
 |
||
 |
||
| If
you don't want to receive any further Joint Care eNews,
please click here to unsubscribe. |
Bioiberica SA follows the Spanish Organic Law 15, 13th of Dec 1999. According to the Spanish organic law of data protection we are obliged to communicate to you that any data that you may provide to us by telephone or written will remain totally confidential in the DB of Bioiberica SA and it will only be used by Bioiberica SA, until you tell us not to continue doing so. You will always have the right to modify any of your data at any time. | ||||
 |
|
||||||||